포머스

비상장계속사업자

Fomers.Co.,Ltd.

강준기

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

포머스

Business Reg. No. 5158136523 · CEO 강준기

I.Investment Overview

Target포머스 (5158136523)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명포머스
영문명Fomers.Co.,Ltd.
대표자강준기
사업자등록번호5158136523
법인등록번호1748110050817
설립일2009.02.26

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW371.42021514.22022429.82023512.12024382.52025
영업이익100M KRW2.8202114.1202213.4202321.82024-10.82025
순이익100M KRW1.920218.420223.4202311.82024-18.82025
Item20252024202320222021
자산총계544억원503.4억원455.2억원429.1억원321.5억원
부채총계406.4억원371억원339.6억원324.8억원248.5억원
자본총계137.5억원132.4억원115.6억원104.2억원73억원
매출액382.5억원512.1억원429.8억원514.2억원371.4억원
영업이익-10.8억원21.8억원13.4억원14.1억원2.8억원
순이익-18.8억원11.8억원3.4억원8.4억원1.9억원

VI.Financial Ratios

FY2025 basis

-2.82%

영업이익률

-4.9%

순이익률

-3.45%

ROA

-13.64%

ROE

295.5%

부채비율

25.28%

자기자본비율

VII.R&D Activity

Fields 재료 > 소성가공/분말

Keywords 지정맥, 헬스케어

YearProjectsPapersPatents
2022101
2021100
2020204
2019101

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

포머스 투심보고서 | Alpha Lenz